COVID-19 Vaccine Allocation Needs Careful Consideration in Context

As the world transitions to a post-Omicron era, researchers have published new findings on the importance of ongoing vaccination to minimize disease burden. According to the University of Melbourne study, careful consideration of vaccine allocation is crucial in response to diverse infection and vaccination histories among populations. The study highlights the need for targeted vaccine use across different country settings to achieve optimal health outcomes.

Key Takeaways:

• The post-Omicron phase of COVID-19 management requires careful consideration of ongoing vaccination to minimize disease burden.
• Targeted vaccine use across different country settings is essential to achieve optimal health outcomes.
• Annual elder-targeted boosting strategies are most likely to be cost-effective or cost-saving in older, high-income settings (75% probability), while paediatric programs are unlikely to be cost-effective.
• Half-yearly boosting may only be cost-effective in higher income settings with older population demographics and higher cost-effectiveness thresholds.
• The study integrated immunological, transmission, clinical, and cost-effectiveness models to simulate populations with different characteristics and immune landscapes over the early post-Omicron period.
• The research found that the biggest health gains relative to vaccine costs are achieved by targeting older age groups.

Statistics:

• 75% probability of cost-effectiveness among older, high-income settings for annual elder-targeted boosting strategies
• 50% probability of cost-effectiveness in younger, middle-income settings for annual elder-targeted boosting strategies
• Estimated costs from a healthcare perspective for exemplar country income-level groupings in the Western Pacific Region using pandemic-era vaccine prices and healthcare-seeking behavior assumptions
• 75% of older, high-income settings are likely to benefit from annual elder-targeted boosting strategies
• 50% of younger, middle-income settings are likely to benefit from annual elder-targeted boosting strategies

Sources:

• University of Melbourne, Department of Medical Biology and Department of Foreign Affairs and Trade, Australian Government and World Health Organization)
• National Health And Medical Research Council
• BMJ Global Health, a dynamic modelling study: Health impact and cost-effectiveness of COVID-19 booster vaccination strategies in the early post-Omicron era
• doi: 10.1136/bmjgh-2024-016096
• https://doi-org.sdpl.idm.oclc.org/10.1136/bmjgh-2024-016096
• BMJ Global Health, 2025, 10(9)
• BMJ Publishing Group, publisher of BMJ Global Health
• https://gh.bmj.com